The effect of amlodipine and enalapril on blood pressure and neurohumoral activation in hypertensive patients with Ribbing's disease (multiple epiphysal dystrophy)

Clinical Cardiology

Volumn 23, Issue 2, 2000, Pages 109-114

  Cocco, Giuseppe ^a,b   Ettlin, Thierry ^a   Baumeler, Hans Ruedi ^a  

^a Rehaklinik Rheinfelden   (Switzerland)

^b NONE   (Switzerland)

Author keywords

Amlodipine; Enalapril; Hypertension; Multiple epiphysal dystrophy; Ribbing's disease

Indexed keywords

AMLODIPINE; ANGIOTENSIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NORADRENALIN;

ADULT; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; MULTIPLE EPIPHYSEAL DYSTROPHY; MULTIPLE MALFORMATION SYNDROME; NORADRENALIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RIBBING DISEASE; SYMPATHETIC TONE; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0033952426     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960230208     Document Type: Article

References (29)

1. Ribbing S: Hereditary, multiple, diaphyseal sclerosis. Acta Radiol 1949;31:522-536
2. Cocco G, Kovac C, Sfrisi C, Pouleur H: Cardiac involvement in Ribbing's disease. Eur Heart J 1994;15:1124-1128
3. Basson CT, Cowley GS, Solomon SD, Weissman B, Poznanski AK, Traill TA, Seidman JG, Seidman CE: The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand-syndrome). N Engl J Med 1994;330:885-891
4. Parati G, Di Rienzo M, Monsignore MR, Marrone O, Castiglioni P, Bonsignore G, Mancia G: Autonomic cardiac regulation in obstructive sleep apnea syndrome: Evidence from spontaneous baroreflex analysis during sleep. J Hypertens 1997;15:1621-1626
5. Mancia G, Zanchetti A: White-coat hypertension: Misnomers, misconceptions and misunderstandings. What should we do next? J Hypertens 1996;15:1049-1052
6. Stella ML, Mircoli L, Magoni AA, Giannattasio C, Ferrara AU, Mancia G: Differential alterations of common carotid and femoral artery distensibility in 12-week-old spontaneously hypertensive rats. J Hypertens 1997;15:1665-1669
7. Failla M, Grappiolo A, Caruga S, Calchera I, Giannattasio C, Mancia G: Effects of cigarette smoking on carotid and radial artery distensibility. J Hypertens 1997;15:1659-1664
8. Mancia G, Sega R, Bravi C, De Vito G, Valagussa F, Cesana G, Zanchetti A: Ambulatory blood pressure normality: Results from the PAMELA study. J Hypertens 1995;13:1377-1390
9. Prattichizzo FA: Considerations on the PAMELA study results concerning ambulatory blood pressure normality. J Hypertens 1996;14:927-928
10. Mancia G, Lanfranchi A, Turri C, Grassi G: Can good surrogate end-points predict the prognosis of hypertensive patients? J Hypertens 1998;16:S3-S7
11. Kappelgaard AM, Nielsen MD, Giese J: Measurement of angiotensin II in human plasma: Technical modifications and practical experience. Clin Chim Acta 1976;67:299-306
12. Searle SR: Linear Models for Unbalanced Data. New York: John Wiley, 1987
13. Bauer P: Multiple testing in clinical trials. Stat Med 1991;10: 871-890
14. Messerli FH: Hypertension in special populations. Med Clin N Am 1997;6:1335-1345
15. Gifford RW Jr: Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists. Med Clin N Am 1997;6:1319-1333
16. Noll G, Wenzel RR, Binggeli C, Corti C, Lüscher TF: Role of the sympathetic nervous system in hypertension and effects of cardiovascular drugs. Eur Heart J 1998;19:F32-F38
17. Sleight P: The sympathetic nervous system in hypertension: Different effects of drug treatment. Eur Heart J 1998;19:F39-F44
18. Grossman E, Messerli FH: Effect of calcium antagonists on sympathetic activity. Eur Heart J 1998;19:F27-F31
19. Julius S: Effect of sympathetic activity on cardiovascular prognosis in hypertension. Eur Heart J 1998;19:F14-F18
20. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse effects of short acting calcium antagonists. In Hypertension, Pathophysiolagy, Diagnosis and Management (Eds. Laragh JH, Brenner BM), p. 2815-2825. New York: Raven Press, 1995
21. Furberg CD, Psaty BM, Meyer JV: Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1997;92:1326
22. Esler M, Jennings G, Lambert G, Meredith I, Home M, Eisenhofer G: Overflow of catecholamine neurotransmitters to the circulation source, fate, and functions. Physiol Rev 1990;70:963-985
23. Mancia G: Bjorn Folkow Award Lecture: The sympathetic nervous system in hypertension. J Hypertens 1997;15:1553-1565
24. Zanchetti A, Mancia G: Strategies for antihypertensive treatment decisions: How to assess benefits? J Hypertens 1997;15:215-216
25. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell' Oro R, Mancia G: Heart rate as marker of sympathetic activity. J Hypertens 1998;16:1635-1639
26. Dahlhöf B, Lindholm LH, Carney S, Pentikäinen PJ, Östergren J: Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens 1997;15:1327-1335
27. Wagner C, Kees F, Krämer BK, Kurz A: Role of the sympathetic nerves for the stimulation of the renin system by angiotensin II receptor blockade. J Hypertens 1997;15:1436-1469
28. Israili Z, Hall WS: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-246
29. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998; 33:784-790